Division of Cardiovascular Medicine, Department of Internal Medicine, Medical Pharmacology and Physiology and Nutrition and Exercise Physiology, Dalton Cardiovascular Research Center, University of Missouri-Columbia, Columbia, MO 65211, USA.
Basic Res Cardiol. 2011 Jan;106(1):111-23. doi: 10.1007/s00395-010-0129-9. Epub 2010 Oct 24.
Protease-activated receptor-2 (PAR2) is expressed in endothelial cells and mediates endothelium-dependent vasodilation. We hypothesized that PAR2 regulates tumor necrosis factor-alpha (TNF-α)-induced coronary arteriolar dysfunction in type 2 diabetic (db/db) mice. To test this, coronary arterioles from WT control, db/db, db/db mice treated with PAR2 antagonist FSLLRY-NH₂ (db/db+FSLLRY-NH₂) and db/db mice null for TNF (db(TNF-)/db(TNF-)) were isolated and pressurized (60 cmH₂O) without flow. Although vasodilation to the endothelium-independent vasodilator sodium nitroprusside (SNP) was not different among WT, db/db, db/db+FSLLRY-NH₂ and db(TNF-)/db(TNF-), endothelium-dependent acetylcholine (ACh)- and flow-mediated vasodilation were impaired in db/db mice but were enhanced in db(TNF-)/db(TNF-) mice and db/db mice treated with PAR2 antagonist. NOS inhibitor N (G)-nitro-L-arginine-methyl ester (L-NAME) significantly reduced ACh-induced dilation in WT, db(TNF-)/db(TNF-) and db/db+FSLLRY-NH₂, but did not alter the vasodilation in db/db mice. In contrast, cyclooxygenase (COX) inhibitor indomethacin (Indo) did not alter ACh-induced vasodilation in these four groups of mice. PAR2-activating peptide (PAR2-AP, 2-Furoyl-LIGRLO-am)-induced dilation was higher in db/db mice than that in WT, db(TNF-)/db(TNF-) and db/db mice treated with PAR2 antagonist. These effects were abolished by denudation, or in the presence of L-NAME or Indo. Protein expressions of TNF-α, PAR2, gp91(phox) and p47(phox) in the heart and isolated coronary arterioles were higher in db/db mice compared to WT mice. Administration of PAR2 antagonist to db/db mice reduced protein expression of TNF-α, gp91(phox) and PAR2. Protein expression of gp91(phox) and p47(phox) was lower in db(TNF-)/db(TNF-) compared to db/db mice. These results indicate that PAR2 plays a pivotal role in endothelial dysfunction in type 2 diabetes by up-regulating the expression/production of TNF-α and activating NAD(P)H oxidase subunit p47(phox).
蛋白酶激活受体 2(PAR2)在血管内皮细胞中表达,并介导内皮依赖性血管舒张。我们假设 PAR2 调节 2 型糖尿病(db/db)小鼠中肿瘤坏死因子-α(TNF-α)诱导的冠状动脉小动脉功能障碍。为了验证这一点,从 WT 对照、db/db、db/db 小鼠用 PAR2 拮抗剂 FSLLRY-NH₂(db/db+FSLLRY-NH₂)和 TNF 缺失的 db(TNF-)/db(TNF-)小鼠中分离并加压(60 cmH₂O)无流量的冠状动脉小动脉。尽管 WT、db/db、db/db+FSLLRY-NH₂ 和 db(TNF-)/db(TNF-)小鼠之间对非内皮依赖性血管扩张剂硝普钠(SNP)的血管舒张没有差异,但 db/db 小鼠的内皮依赖性乙酰胆碱(ACh)和血流介导的血管舒张受损,而 db(TNF-)/db(TNF-)小鼠和 db/db 小鼠用 PAR2 拮抗剂处理后增强。一氧化氮合酶抑制剂 N(G)-硝基-L-精氨酸甲酯(L-NAME)显著降低了 WT、db(TNF-)/db(TNF-)和 db/db+FSLLRY-NH₂ 中 ACh 诱导的扩张,但未改变 db/db 小鼠的血管舒张。相比之下,环加氧酶(COX)抑制剂吲哚美辛(Indo)并未改变这四组小鼠中 ACh 诱导的血管舒张。与 WT、db(TNF-)/db(TNF-)和 db/db 小鼠用 PAR2 拮抗剂处理的小鼠相比,db/db 小鼠中 PAR2 激活肽(PAR2-AP,2-呋喃酰基-LIGRLO-am)诱导的扩张更高。这些作用被去内皮、或存在 L-NAME 或 Indo 时消除。与 WT 小鼠相比,db/db 小鼠心脏和分离的冠状动脉小动脉中 TNF-α、PAR2、gp91(phox)和 p47(phox)的蛋白表达更高。给予 db/db 小鼠 PAR2 拮抗剂可降低 TNF-α、gp91(phox)和 PAR2 的蛋白表达。与 db/db 小鼠相比,db(TNF-)/db(TNF-)小鼠的 gp91(phox)和 p47(phox)蛋白表达更低。这些结果表明,PAR2 通过上调 TNF-α的表达/产生和激活 NAD(P)H 氧化酶亚基 p47(phox),在 2 型糖尿病中的内皮功能障碍中发挥关键作用。